Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T (2017) Exenatide once weekly versus placebo in Parkinsons disease: a randomised, double-blind, placebo-controlled trial
it emerges over the following weeks as the level plateaus
Extremely low body weight or BMI GLP-1 medications are designed for overweight and obese individuals
For a deep dive into the differences, see our complete guide on which water to mix with peptides
Pay attention to how your body responds during this jump
Data on perioperative management of GLP1-RAs were available in 93% of all patients, of whom 92% had continued their usual GLP1-RA regimen perioperatively, and the median LOS was one (IQR: 1-1) day